Literature DB >> 18258632

Sensitive detection of cereal fractions that are toxic to celiac disease patients by using monoclonal antibodies to a main immunogenic wheat peptide.

Belén Morón1, Angel Cebolla, Hamid Manyani, Moisés Alvarez-Maqueda, Manuel Megías, María Del Carmen Thomas, Manuel Carlos López, Carolina Sousa.   

Abstract

BACKGROUND: Celiac disease is an immune-mediated enteropathy caused by the ingestion of gluten, a protein fraction found in certain cereals. Immunotoxic gluten peptides that are recalcitrant to degradation of digestive enzymes appear to trigger celiac syndromes. A 33-mer peptide from alpha-2 gliadin has been identified as a principal contributor to gluten immunotoxicity. A gluten-free diet is the usual first therapy for celiac disease patients; therefore, the characterization and quantification of the toxic portion of the gluten in foodstuffs is crucial to avoid celiac damage.
OBJECTIVE: We aimed to develop immunologic assays as a novel food analysis tool for measuring cereal fractions that are immunotoxic to celiac disease patients.
DESIGN: The design focused on the production of monoclonal antibodies against the gliadin 33-mer peptide and the development of enzyme-linked immunosorbent assays (ELISAs) and Western blot analysis with the use of novel antibodies.
RESULTS: A sandwich ELISA method showed a detection limit for wheat, barley, and rye of <1 ppm prolamine. However, the method required a sample that was > or =1 order of magnitude greater for the detection of low-toxic oats, and there was no signal with the safe cereals maize and rice. A competitive ELISA method was also developed for detection of the toxic peptide in hydrolyzed food, which had a detection limit of <0.5 ppm gliadin.
CONCLUSIONS: Both ELISAs designed for use with the toxic gliadin 33-mer peptide suggested a high correlation between the presence of the peptide and the amount of cereal that was toxic to celiac disease patients. The sensitivity was significantly higher than that of equivalent methods recognizing other gluten epitopes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18258632     DOI: 10.1093/ajcn/87.2.405

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  40 in total

1.  Preparation of gluten-free rice spaghetti with soy protein isolate using twin-screw extrusion.

Authors:  Pakkawat Detchewa; Masubon Thongngam; Jay-Lin Jane; Onanong Naivikul
Journal:  J Food Sci Technol       Date:  2016-09-12       Impact factor: 2.701

2.  A gluten metabolism study in healthy individuals shows the presence of faecal glutenasic activity.

Authors:  Alberto Caminero; Esther Nistal; Laura Arias; Santiago Vivas; Isabel Comino; Ana Real; Carolina Sousa; José M Ruiz de Morales; Miguel A Ferrero; Leandro B Rodríguez-Aparicio; Javier Casqueiro
Journal:  Eur J Nutr       Date:  2011-06-14       Impact factor: 5.614

3.  Magnetic Optical Microarray Imager for Diagnosing Type of Diabetes in Clinical Blood Serum Samples.

Authors:  Vini Singh; Cassandra Rodenbaugh; Sadagopan Krishnan
Journal:  ACS Sens       Date:  2016-02-18       Impact factor: 7.711

4.  Oral enzyme therapy for celiac sprue.

Authors:  Michael T Bethune; Chaitan Khosla
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

5.  Identification of Pseudolysin (lasB) as an Aciduric Gluten-Degrading Enzyme with High Therapeutic Potential for Celiac Disease.

Authors:  Guoxian Wei; Na Tian; Adriana C Valery; Yi Zhong; Detlef Schuppan; Eva J Helmerhorst
Journal:  Am J Gastroenterol       Date:  2015-04-21       Impact factor: 10.864

6.  Identification of food-grade subtilisins as gluten-degrading enzymes to treat celiac disease.

Authors:  Guoxian Wei; Na Tian; Roland Siezen; Detlef Schuppan; Eva J Helmerhorst
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-07-28       Impact factor: 4.052

7.  Noninflammatory gluten peptide analogs as biomarkers for celiac sprue.

Authors:  Michael T Bethune; Mónica Crespo-Bosque; Elin Bergseng; Kaushiki Mazumdar; Lara Doyle; Karol Sestak; Ludvig M Sollid; Chaitan Khosla
Journal:  Chem Biol       Date:  2009-08-28

Review 8.  Celiac disease: understanding the gluten-free diet.

Authors:  Karla A Bascuñán; María Catalina Vespa; Magdalena Araya
Journal:  Eur J Nutr       Date:  2016-06-22       Impact factor: 5.614

9.  Protein engineering of improved prolyl endopeptidases for celiac sprue therapy.

Authors:  Jennifer Ehren; Sridhar Govindarajan; Belén Morón; Jeremy Minshull; Chaitan Khosla
Journal:  Protein Eng Des Sel       Date:  2008-10-04       Impact factor: 1.650

10.  Engineering of Kuma030: A Gliadin Peptidase That Rapidly Degrades Immunogenic Gliadin Peptides in Gastric Conditions.

Authors:  Clancey Wolf; Justin B Siegel; Christine Tinberg; Alessandra Camarca; Carmen Gianfrani; Shirley Paski; Rongjin Guan; Gaetano Montelione; David Baker; Ingrid S Pultz
Journal:  J Am Chem Soc       Date:  2015-09-29       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.